Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.262
Index Copernicus (ICV) – 155.19, MNiSW – 15
Rejection rate – 65.13%
License – Creative Commons: Attribution 3.0 Unported (CC BY 3.0)
ISSN 1899–5276 (print),   ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 5, September-October, p. 791–800

doi: 10.17219/acem/44361

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Determinants of Elevated Levels of Natural Anticoagulants in Healthy Subjects

Barbara Kościelniak1,B,C,D, Ewa Wypasek2,B,C,D, Anetta Undas2,A,E,F

1 John Paul II Hospital, Kraków, Poland

2 Institute of Cardiology, John Paul II Hospital, Jagiellonian University Medical College, Kraków, Poland


Background. The levels of protein C (PC), free protein S (PS) and antithrombin (AT) are evaluated during thrombophilia screening to exclude their deficiencies.
Objectives. The aim of this study was to investigate factors which determine the elevated levels of natural plasma anticoagulants in healthy individuals.
Material and Methods. The PC activity and antigen, free PS antigen and AT activity together with hematological, biochemical, genetic and immunological laboratory tests were assessed in 130 healthy adults (63 males) aged 20–60 (median 41) years. Individuals with personal or family history of cardiovascular diseases and venous thromboembolism were ineligible.
Results. The functionally active PC measured by chromogenic assay (values above 140%) was observed in 14 (11%) of subjects, while the PC antigen determined using the enzyme-linked immunosorbent assay (ELISA) was elevated in 5 (4%) of these patients. Free PS measured by immunoturbidimetry and ELISA was increased in 9 (7%) subjects (values above 139% in men and 114% for women) and in 6 (5%) patients (values above 130% in men and 111% for women), respectively. The AT activity above 118% was found in 5 (4%) subjects measured using chromogenic assay. None of the individuals had any deficiency of natural anticoagulants. Increased C-reactive protein (CRP) > 3.0 mg/L was associated with elevated PC activity (odd ratio [OR]: 11.14, 95% confidence interval [CI] 1.67–74.23). Increased free PS assessed by immunoturbidimetric assay and PC activity were associated with hypercholesterolemia (OR: 3.57, 95% CI: 1.09–10.06 and OR: 8.61, 95% CI: 1.07–69.04, respectively). Body mass index ≥ 25 kg/m2 was independently associated with elevated PC activity (OR: 3.42, 95% CI: 1.01–11.52). No risk factors for elevated AT activity were identified.
Conclusion. Apart from hypercholesterolemia and overweight, increased serum CRP is associated with elevated PC activity in healthy adults. We confirmed that there are differences in the proportions of subjects with elevated PC and PS depending on the assay used.

Key words

protein C, protein S, antithrombin

References (30)

  1. Griffin JH, Fernández JA, Gale AJ, Mosnier LO: Activated protein C. J Thromb Haemost 2007, 5, 73–80.
  2. Xu J, Esmon NL, Esmon CT: Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 1999, 274, 6704–6710.
  3. Wypasek E, Undas A: Protein C and protein S deficiency – practical diagnostic issues. Adv Clin Exp Med 2013, 22, 459–467.
  4. Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton JW, Andrew M, Delorme M, Ginsberg J, Preissner KT: Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995, 73, 405–412.
  5. Rao LVM, Nordfang O, Hoang AD, Pendurthi UR: Mechanism of antithrombin III inhibition of factorVIIa/tissue factor activity on cell surfaces: comparison with tissue factor pathway inhibitor/factor Xa – induced inhibition of factorVIIa/tissue factor activity. Blood 1995, 85, 121–129.
  6. Kyrle PA: Venous thrombosis: who should be screened for thrombophilia in 2014? Pol Arch Med Wewn 2014, 124, 65–69.
  7. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, De Stefano V, Palareti G, Finazzi G, Baudo F, Quintavalla R: Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999, 19, 1026–1033.
  8. Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman MV, Prandoni P, Bura A, Rejto L, Wells P, Mannucci PM, Girolami A, Büller HR, Prins MH: The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999, 94, 3702–3706.
  9. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC: A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001, 113, 636–341.
  10. Tait RC, Walker ID, Islam SI, McCall F, Conkie JA, Mitchell R, Davidson JF: Influence of demographic factors in antithrombin III activity in a healthy population. Br J Haematol 1993, 84, 476–480.
  11. Dolan G, Neal K, Cooper P, Brown P, Preston FE: Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994, 86, 798–803.
  12. Rodeghiero F, Tosetto A: The VITA Project: population-based distributions of protein C, antithrombin III, heparincofactor II and plasminogen – relationship with physiological variables and establishment of reference ranges. Thromb Haemost 1996, 76, 226–233.
  13. Boerger LM, Morris PC, Thurnau GR, Esmon CT, Comp PC: Oral contraceptives and gender affect protein S status. Blood 1987, 69, 692–694.
  14. MacCallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ: Associations of protein C and protein S with serum lipid concentrations. Br J Haematol 1998, 102, 609–615.
  15. Franchi F, Biguzzi E, Martinelli I, Bucciarelli P, Palmucci C, D’Agostino S, Peyvandi F: Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. Thromb Res 2013, 132, 152–157.
  16. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK: Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993, 70, 762–767.
  17. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, Morrison CE: Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997, 97, 785–797.
  18. Assmann G, Schulte H: The importance of triglycerides: results from the Prospective Cardiovascular Münster (PROCAM) Study. Eur J Epidemiol 1992, 8, 99–103.
  19. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ: C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004, 109, 2566–25671.
  20. Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107, 398–404.
  21. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82, 513–520.
  22. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005, 13, 417–430.
  23. Owczarek D, Cibor D, Sałapa K, Cieśla A, Głowacki MK, Pocztar H, Mach TH: Anti-inflammatory and anticoagulant properties of the protein C system in inflammatory bowel disease. Pol Arch Med Wewn 2012, 122, 209–216.
  24. Kroll MH: Evaluating interference caused by lipemia. Clin Chem 2004, 50, 1968–1969.
  25. Tate J, Ward G: Interferences in immunoassay. Clin Biochem Rev 2004, 25, 105–120.
  26. Lippi G, Plebani M, Favaloro EJ: Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013, 39, 258–266.
  27. Nikolac N: Lipemia: causes, interference mechanisms, detection and management. Biochem Med (Zagreb) 2014, 24, 57–67.
  28. Kim JA, Kim JE, Song SH, Kim HK: Influence of blood lipids on global coagulation test results. Ann Lab Med 2015, 35, 15–21.
  29. Solá E, Navarro S, Medina P, Vayá A, Estellés A, Hernández-Mijares A, España F: Activated protein C levels in obesity and weight loss influence. Thromb Res 2009, 123, 697–700.
  30. DePergola G, Pannacciulli N: Coagulation and fibrinolys is abnormalities in obesity. J Endocrinol Invest 2002, 25, 899–904.